Clinical development is becoming increasingly complex with continuing innovations in cellular and gene therapies, especially when factoring in the hurdles of rare disease research. Understanding and proactively addressing common medical, operational, and regulatory considerations ensures that a trial is best positioned for success. To achieve cellular and gene therapy approvals in rare diseases, it is essential to overcome challenges specific to these trials.
In this recent Rare Disease Day webinar, Medpace medical, regulatory, and operational experts discuss successful approaches for achieving cellular and gene therapy approvals in rare diseases.
Watch Now
Innovative Patient Recruitment and Retention Approaches for Rare Disease Clinical Trials
Medpace is recognized globally as a leading CRO for rare diseases, having contributed to over 250 rare disease clinical trials across a broad range of rare disease indications spanning all ages and in a spectrum of therapeutic areas, including neuroscience, metabolic, cardiovascular, and ophthalmology. Overcome challenges and drive patient enrollment with Medpace’s strong site relationships and extensive rare disease experience in scarce patient populations.
Learn more about Medpace’s rare disease capabilities.
